首頁 > 市場調查報告書 > 製藥

DDS

市場調查報告書

商品編碼

2021635

固態製劑市場預測至2034年－全球分析（按劑型、藥物釋放、給藥途徑、治療領域、生產流程、藥物類型、病患群體、最終用戶、分銷管道和地區分類）

Solid Dosage Form Market Forecasts to 2034 - Global Analysis By Dosage Form, Drug Release, Route of Administration, Therapeutic Area, Manufacturing Process, Drug Type, Patient Demographics, End User, Distribution Channel, and By Geography

出版日期: 2026年04月17日 | 出版商:

Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

簡介目錄圖表

根據 Stratistics MRC 的數據，預計到 2026 年，全球固態劑型市場規模將達到 11136 億美元，並在預測期內以 6.6% 的複合年成長率成長，到 2034 年將達到 18569 億美元。

固態劑型是指口服或其他固態給藥途徑的藥物，例如藥片、膠囊、粉末和顆粒劑。由於其穩定性好、劑量精準、服用方便且生產成本低，這些製劑是應用最廣泛的給藥方式。推動這一市場發展的因素包括慢性病盛行率的上升、需要長期用藥的老年人口不斷增加，以及緩釋技術和以患者為中心的製劑的持續創新。

慢性病盛行率增加

全球慢性疾病（如心血管疾病、糖尿病、呼吸系統疾病和癌症）的日益增多，推動了對能夠實現長期疾病管理的固態劑型的持續需求。對於需要每日或頻繁服藥的患者而言，片劑和膠囊劑的便利性和精確劑量具有顯著優勢。製藥公司正致力於開發複方製劑，將複雜的治療方案簡化為單一的固態劑型，從而提高患者的用藥依從性。隨著全球慢性疾病負擔的持續加重，可靠、可規模化生產且患者用藥方便的固態劑型仍然是全球藥品生產和醫療保健服務的基礎。

開發難溶性藥物的複雜性

藥物研發管線中湧現的大量新型化合物水溶性低，為固態製劑的開發帶來了巨大挑戰。製劑研發人員必須採用脂質系統、奈米研磨和無定形固體分散體等先進技術才能達到足夠的生物利用度，這導致研發時間和生產成本增加。這些技術壁壘會延緩產品上市，並限制固態製劑在特定治療領域的應用。中小型製藥公司可能缺乏必要的設備和專業知識，從而限制其在複雜候選藥物普遍存在的市場中的競爭力。

連續製造技術的擴展

在固態製劑生產中採用連續生產技術，可顯著提升效率、品質並符合法規要求。與傳統的間歇式生產不同，連續生產整合了即時監控和製程分析技術，能夠縮短生產週期、減少廢棄物並確保產品品質的穩定性。監管機構正透過簡化核准流程來鼓勵這種生產方式。隨著製藥公司對老舊設施進行現代化改造，並著手解決疫情期間暴露出的供應鏈脆弱性問題，對片劑和膠囊連續生產平台的投資正在加速成長，這為技術供應商和契約製造組織 (CMO) 創造了巨大的發展機會。

來自其他劑型的競爭加劇

口溶錠、經皮吸收貼片、注射用生物製劑和液體製劑等替代給藥系統的日益普及，對傳統固態劑型構成了競爭。尋求更便利用藥、更快起效或解決吞嚥困難的患者可能更傾向於選擇這些替代劑型。兒童和老年人尤其推動了對非固態劑型的需求。此外，生物製藥革命正在促進腸外給藥的發展，並將研發投資從傳統固態劑型平台轉移出去。如果固態劑型的創新無法跟上患者偏好和治療需求的變化，這種轉變可能會導致市場佔有率的萎縮。

新冠疫情的影響：

新冠疫情為固態製劑市場帶來了挑戰與機會。初期封鎖措施擾亂了供應鏈，減少了門診就診量，暫時影響了慢性病藥物的處方。然而，用於治療新冠肺炎的口服抗病毒藥物的快速研發和分發，凸顯了固態製劑在對抗疫情中的關鍵作用。疫情也加速了數位化醫療的普及，促進了電子處方箋和電子藥物宅配。製藥公司透過製造地多元化和投資先進生產技術，增強了供應鏈的韌性，為後疫情時代醫療保健環境下的永續市場成長奠定了基礎。

在預測期內，製藥公司板塊預計將佔據最大的市場佔有率。

預計在預測期內，製藥公司將佔據最大的市場佔有率，這主要得益於這些企業在藥品研發、生產和商業化過程中所扮演的核心角色。製藥公司在研發方面投入巨資，致力於開發創新固態製劑，例如複方組合藥物和用於治療難治性疾病的特效片劑。憑藉其完善的品管系統、豐富的監管經驗和廣泛的分銷網路，製藥公司在各個治療領域均保持領先地位。此外，製藥公司持續自主生產高價值固態製劑，也確保了其在固態製劑技術和服務終端用戶消費領域持續保持主導地位。

在預測期內，線上藥局領域預計將呈現最高的複合年成長率。

在預測期內，線上藥局領域預計將呈現最高的成長率，這反映了醫療服務交付的快速數位轉型以及消費者對便捷取藥方式的偏好。患者擴大使用獲得許可的線上藥局訂購慢性病藥物並宅配，享受價格優勢、自動續方和注重隱私的服務。疫情永久改變了人們的購買習慣，即使實體藥局重新開業，許多消費者仍然傾向於選擇線上管道。重點市場加強遠端醫療和電子處方箋法規結構，進一步推動了這一管道的擴張。隨著數位健康生態系統的日益成熟，線上藥局正成為固態劑型藥物的首選通路。

市佔率最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率，這得益於其成熟的製藥產業、完善的醫療保健基礎設施以及較高的患者健康意識。眾多跨國製藥公司、契約製造組織 (CMO) 和先進的研究機構的存在，推動了固態製劑技術的持續創新。有利的醫保報銷政策和數位醫療工具的廣泛應用，促進了全部區域處方藥的強勁消費。此外，人口老化以及心血管疾病和糖尿病等慢性病的高發生率，也持續推高了對固態製劑的需求，從而鞏固了北美在整個預測期內的市場領先地位。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於醫療基礎設施的快速發展、藥品生產能力的擴張以及慢性病負擔的日益加重。中國、印度和韓國等國家正在崛起為全球固態製劑生產中心，吸引了大量投資用於尖端製造技術。政府推行的學名藥和全民健保措施正在改善患者獲得必需固態製劑的途徑。可支配收入的增加以及對便捷口服療法需求的成長進一步推動了市場成長。隨著跨國製藥公司在該地區擴大企業發展，亞太地區正鞏固其作為全球成長最快市場的地位。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

企業概況
- 對其他市場參與者（最多 3 家公司）進行全面分析
- 對主要公司進行SWOT分析（最多3家公司）
區域分類
- 應客戶要求，我們提供主要國家和地區的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
競爭性標竿分析
- 根據產品系列、地理覆蓋範圍和策略聯盟對重點公司進行基準分析。

北美洲
- 美國
- 加拿大
- 墨西哥
歐洲
- 英國
- 德國
- 法國
- 義大利
- 西班牙
- 荷蘭
- 比利時
- 瑞典
- 瑞士
- 波蘭
- 其他歐洲國家
亞太地區
- 中國
- 日本
- 印度
- 韓國
- 澳洲
- 印尼
- 泰國
- 馬來西亞
- 新加坡
- 越南
- 其他亞太國家
南美洲
- 巴西
- 阿根廷
- 哥倫比亞
- 智利
- 秘魯
- 其他南美國家
世界其他地區（RoW）
- 中東
  - 沙烏地阿拉伯
  - 阿拉伯聯合大公國
  - 卡達
  - 以色列
  - 其他中東國家
- 非洲
  - 南非
  - 埃及
  - 摩洛哥
  - 其他非洲國家

第15章策略市場資訊

工業價值網路和供應鏈評估
空白區域和機會地圖
產品演進與市場生命週期分析
通路、經銷商和打入市場策略的評估

第16章產業趨勢與策略舉措

併購
夥伴關係、聯盟、合資企業
新產品發布和認證
擴大生產能力和投資
其他策略舉措

第17章：公司簡介

Catalent Inc.
Lonza Group AG
Recipharm AB
Aenova Group
Thermo Fisher Scientific Inc.
Pfizer Inc.
Novartis AG
Roche Holding AG
Sun Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Ltd.
Dr. Reddy's Laboratories Limited
Viatris Inc.
Sanofi SA
Abbott Laboratories
Bayer AG
GlaxoSmithKline plc

簡介目錄圖表

Product Code: SMRC35030

According to Stratistics MRC, the Global Solid Dosage Form Market is accounted for $1113.6 billion in 2026 and is expected to reach $1856.9 billion by 2034 growing at a CAGR of 6.6% during the forecast period. Solid dosage forms encompass pharmaceutical products such as tablets, capsules, powders, and granules that are administered orally or via other solid-based delivery routes. These formulations represent the most widely adopted drug delivery method due to their stability, precise dosing, patient convenience, and cost-effectiveness in manufacturing. The market is driven by the rising prevalence of chronic diseases, growing geriatric population requiring long-term medication, and continuous innovation in modified-release technologies and patient-centric formulations.

Market Dynamics:

Driver:

Increasing prevalence of chronic diseases

The global rise in chronic conditions such as cardiovascular disorders, diabetes, respiratory ailments, and cancer is fueling sustained demand for solid dosage forms that enable long-term disease management. Patients requiring daily or frequent medication regimens benefit from the convenience and precise dosing that tablets and capsules offer. Pharmaceutical companies are focusing on developing combination products that simplify complex treatment protocols into single solid dosage units, improving patient adherence. As the global burden of chronic diseases continues to escalate, the need for reliable, scalable, and patient-friendly solid formulations remains a cornerstone of pharmaceutical manufacturing and healthcare delivery worldwide.

Restraint:

Complexity in developing poorly soluble drugs

A significant proportion of new chemical entities emerging from drug discovery pipelines exhibit poor aqueous solubility, posing substantial challenges for solid dosage form development. Formulators must employ advanced technologies such as lipid-based systems, nanomilling, and amorphous solid dispersions to achieve adequate bioavailability, increasing development timelines and manufacturing costs. These technical hurdles can delay product launches and limit the feasibility of solid formulations for certain therapeutic classes. Smaller pharmaceutical companies may lack the specialized equipment and expertise required, potentially restricting their ability to compete in markets dominated by complex drug candidates.

Opportunity:

Expansion of continuous manufacturing technologies

The adoption of continuous manufacturing in solid dosage form production offers transformative opportunities for efficiency, quality, and regulatory compliance. Unlike traditional batch processing, continuous manufacturing integrates real-time monitoring and process analytical technology, enabling faster production cycles, reduced waste, and consistent product quality. Regulatory agencies are encouraging these approaches through streamlined approval pathways. As pharmaceutical companies seek to modernize aging facilities and respond to supply chain vulnerabilities exposed during the pandemic, investment in continuous manufacturing platforms for tablets and capsules is accelerating, creating significant growth opportunities for technology providers and contract manufacturing organizations.

Threat:

Intensifying competition from alternative dosage forms

The growing popularity of alternative drug delivery systems such as orally disintegrating tablets, transdermal patches, injectable biologics, and liquid formulations poses a competitive threat to traditional solid dosage forms. Patients seeking greater convenience, faster onset of action, or solutions for swallowing difficulties may prefer these alternatives. Pediatric and geriatric populations, in particular, drive demand for non-solid options. Additionally, the biologic drug revolution favors parenteral delivery, diverting research and development investment away from conventional solid platforms. This shift could erode market share if solid dosage innovation fails to keep pace with evolving patient preferences and therapeutic requirements.

Covid-19 Impact:

The COVID-19 pandemic created both disruptions and opportunities for the solid dosage form market. Initial lockdowns caused supply chain interruptions and reduced outpatient visits, temporarily affecting prescription volumes for chronic medications. However, the rapid development and distribution of oral antivirals for COVID-19 treatment demonstrated the critical role of solid dosage forms in pandemic response. The crisis also accelerated digital health adoption, boosting e-prescriptions and home delivery of medications. Pharmaceutical companies reinforced supply chain resilience by diversifying manufacturing sites and investing in advanced production technologies, positioning the market for sustained growth in the post-pandemic healthcare landscape.

The Pharmaceutical Companies segment is expected to be the largest during the forecast period

The Pharmaceutical Companies segment is expected to account for the largest market share during the forecast period, driven by the central role these organizations play in drug development, manufacturing, and commercialization. Pharmaceutical companies invest heavily in research and development to create innovative solid dosage formulations, including fixed-dose combinations and specialty tablets for complex diseases. Their established quality systems, regulatory expertise, and extensive distribution networks enable them to maintain leadership across therapeutic categories. Additionally, the ongoing trend toward in-house manufacturing of high-value solid dosage products ensures that pharmaceutical companies continue to dominate end-user consumption of solid dosage form technologies and services.

The Online Pharmacies segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the Online Pharmacies segment is predicted to witness the highest growth rate, reflecting the rapid digital transformation of healthcare delivery and consumer preference for convenient medication access. Patients increasingly turn to licensed e-pharmacies for home delivery of chronic medications, benefiting from competitive pricing, automatic refills, and discreet service. The pandemic permanently shifted buying habits, with many consumers continuing to prefer online channels even after physical pharmacies reopened. Enhanced regulatory frameworks for telemedicine and e-prescribing in major markets further support this channel's expansion. As digital health ecosystems mature, online pharmacies are becoming a preferred distribution route for solid dosage products.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, underpinned by a well-established pharmaceutical industry, strong healthcare infrastructure, and high patient awareness. The presence of numerous multinational pharmaceutical companies, contract manufacturing organizations, and advanced research institutions drives continuous innovation in solid dosage technologies. Favorable reimbursement policies and widespread adoption of digital health tools support robust prescription drug consumption across the region. Additionally, the aging population and high prevalence of chronic diseases such as cardiovascular conditions and diabetes create sustained demand for solid dosage forms, cementing North America's market leadership throughout the forecast period.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, fueled by rapid healthcare infrastructure development, expanding pharmaceutical manufacturing capabilities, and growing chronic disease burden. Countries including China, India, and South Korea are emerging as global hubs for solid dosage production, attracting significant investment in modern manufacturing technologies. Government initiatives promoting generic medicines and universal healthcare coverage increase accessibility to essential solid dosage formulations. Rising disposable incomes and growing patient populations seeking convenient oral therapies further drive market expansion. As multinational pharmaceutical companies expand their footprint in the region, Asia Pacific solidifies its position as the fastest-growing market.

Key players in the market

Some of the key players in Solid Dosage Form Market include Catalent Inc., Lonza Group AG, Recipharm AB, Aenova Group, Thermo Fisher Scientific Inc., Pfizer Inc., Novartis AG, Roche Holding AG, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Limited, Viatris Inc., Sanofi S.A., Abbott Laboratories, Bayer AG, and GlaxoSmithKline plc.

Key Developments:

In March 2026, Catalent announced a global partnership with GelMEDIX for the development and clinical manufacturing of iPSC-derived therapies, utilizing its advanced formulation expertise.

In March 2026, Thermo Fisher Scientific Inc. completed the acquisition of Clario Holdings, Inc., enhancing its clinical trial services and logistics for solid dosage medications globally.

In November 2025, Partnered with AstraZeneca Pharma India to distribute therapies for Hyperkalaemia, focusing on expanding the reach of critical solid dose treatments in emerging markets.

Dosage Forms Covered:

Tablets
Capsules
Powders & Granules
Lozenges & Pastilles
Pellets & Mini-Tablets
Orally Disintegrating Films
Other Dosage Forms

Drug Releases Covered:

Immediate Release
Modified Release
Sustained Release
Extended Release
Controlled Release
Delayed Release (Enteric-Coated)
Targeted Drug Delivery Systems

Route of Administrations Covered:

Oral
Buccal
Sublingual

Therapeutic Areas Covered:

Cardiovascular Diseases
Oncology
Central Nervous System (CNS) Disorders
Anti-Infectives
Gastrointestinal Disorders
Respiratory Diseases
Metabolic Disorders
Pain Management
Other Therapeutic Areas

Manufacturing Process Covered:

Direct Compression
Wet Granulation
Dry Granulation
Extrusion-Spheronization
Coating Technologies
Film Coating
Sugar Coating
Enteric Coating

Drug Types Covered:

Branded Drugs
Generic Drugs
Over-the-Counter (OTC) Drugs

Patient Demographics Covered:

Adult Population
Pediatric Population
Geriatric Population

End Users Covered:

Pharmaceutical Companies
Contract Development & Manufacturing Organizations (CDMOs)
Research Institutes

Distribution Channels Covered:

Hospital Pharmacies
Retail Pharmacies
Drug Stores
Online Pharmacies

Regions Covered:

North America
- United States
- Canada
- Mexico
Europe
- United Kingdom
- Germany
- France
- Italy
- Spain
- Netherlands
- Belgium
- Sweden
- Switzerland
- Poland
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Vietnam
- Rest of Asia Pacific
South America
- Brazil
- Argentina
- Colombia
- Chile
- Peru
- Rest of South America
Rest of the World (RoW)
- Middle East
Saudi Arabia
United Arab Emirates
Qatar
Israel
Rest of Middle East
- Africa
South Africa
Egypt
Morocco
Rest of Africa

What our report offers:

Market share assessments for the regional and country-level segments
Strategic recommendations for the new entrants
Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary

1.1 Market Snapshot and Key Highlights
1.2 Growth Drivers, Challenges, and Opportunities
1.3 Competitive Landscape Overview
1.4 Strategic Insights and Recommendations

2 Research Framework

2.1 Study Objectives and Scope
2.2 Stakeholder Analysis
2.3 Research Assumptions and Limitations
2.4 Research Methodology
- 2.4.1 Data Collection (Primary and Secondary)
- 2.4.2 Data Modeling and Estimation Techniques
- 2.4.3 Data Validation and Triangulation
- 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

3.1 Market Definition and Structure
3.2 Key Market Drivers
3.3 Market Restraints and Challenges
3.4 Growth Opportunities and Investment Hotspots
3.5 Industry Threats and Risk Assessment
3.6 Technology and Innovation Landscape
3.7 Emerging and High-Growth Markets
3.8 Regulatory and Policy Environment
3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

4.1 Porter's Five Forces Analysis
- 4.1.1 Supplier Bargaining Power
- 4.1.2 Buyer Bargaining Power
- 4.1.3 Threat of Substitutes
- 4.1.4 Threat of New Entrants
- 4.1.5 Competitive Rivalry
4.2 Market Share Analysis of Key Players
4.3 Product Benchmarking and Performance Comparison

5 Global Solid Dosage Form Market, By Dosage Form

5.1 Tablets
- 5.1.1 Immediate Release Tablets
- 5.1.2 Chewable Tablets
- 5.1.3 Effervescent Tablets
- 5.1.4 Enteric-Coated Tablets
- 5.1.5 Film-Coated Tablets
- 5.1.6 Orally Disintegrating Tablets
5.2 Capsules
- 5.2.1 Hard Gelatin Capsules
- 5.2.2 Soft Gelatin Capsules
5.3 Powders & Granules
5.4 Lozenges & Pastilles
5.5 Pellets & Mini-Tablets
5.6 Orally Disintegrating Films
5.7 Other Dosage Forms

6 Global Solid Dosage Form Market, By Drug Release

6.1 Immediate Release
6.2 Modified Release
6.3 Sustained Release
6.4 Extended Release
6.5 Controlled Release
6.6 Delayed Release (Enteric-Coated)
6.7 Targeted Drug Delivery Systems

7 Global Solid Dosage Form Market, By Route of Administration

7.1 Oral
7.2 Buccal
7.3 Sublingual

8 Global Solid Dosage Form Market, By Therapeutic Area

8.1 Cardiovascular Diseases
8.2 Oncology
8.3 Central Nervous System (CNS) Disorders
8.4 Anti-Infectives
8.5 Gastrointestinal Disorders
8.6 Respiratory Diseases
8.7 Metabolic Disorders
8.8 Pain Management
8.9 Other Therapeutic Areas

9 Global Solid Dosage Form Market, By Manufacturing Process

9.1 Direct Compression
9.2 Wet Granulation
9.3 Dry Granulation
9.4 Extrusion-Spheronization
9.5 Coating Technologies
9.6 Film Coating
9.7 Sugar Coating
9.8 Enteric Coating

10 Global Solid Dosage Form Market, By Drug Type

10.1 Branded Drugs
10.2 Generic Drugs
10.3 Over-the-Counter (OTC) Drugs

11 Global Solid Dosage Form Market, By Patient Demographics

11.1 Adult Population
11.2 Pediatric Population
11.3 Geriatric Population

12 Global Solid Dosage Form Market, By End User

12.1 Pharmaceutical Companies
12.2 Contract Development & Manufacturing Organizations (CDMOs)
12.3 Research Institutes

13 Global Solid Dosage Form Market, By Distribution Channel

13.1 Hospital Pharmacies
13.2 Retail Pharmacies
13.3 Drug Stores
13.4 Online Pharmacies

14 Global Solid Dosage Form Market, By Geography

14.1 North America
- 14.1.1 United States
- 14.1.2 Canada
- 14.1.3 Mexico
14.2 Europe
- 14.2.1 United Kingdom
- 14.2.2 Germany
- 14.2.3 France
- 14.2.4 Italy
- 14.2.5 Spain
- 14.2.6 Netherlands
- 14.2.7 Belgium
- 14.2.8 Sweden
- 14.2.9 Switzerland
- 14.2.10 Poland
- 14.2.11 Rest of Europe
14.3 Asia Pacific
- 14.3.1 China
- 14.3.2 Japan
- 14.3.3 India
- 14.3.4 South Korea
- 14.3.5 Australia
- 14.3.6 Indonesia
- 14.3.7 Thailand
- 14.3.8 Malaysia
- 14.3.9 Singapore
- 14.3.10 Vietnam
- 14.3.11 Rest of Asia Pacific
14.4 South America
- 14.4.1 Brazil
- 14.4.2 Argentina
- 14.4.3 Colombia
- 14.4.4 Chile
- 14.4.5 Peru
- 14.4.6 Rest of South America
14.5 Rest of the World (RoW)
- 14.5.1 Middle East
  - 14.5.1.1 Saudi Arabia
  - 14.5.1.2 United Arab Emirates
  - 14.5.1.3 Qatar
  - 14.5.1.4 Israel
  - 14.5.1.5 Rest of Middle East
- 14.5.2 Africa
  - 14.5.2.1 South Africa
  - 14.5.2.2 Egypt
  - 14.5.2.3 Morocco
  - 14.5.2.4 Rest of Africa

15 Strategic Market Intelligence

15.1 Industry Value Network and Supply Chain Assessment
15.2 White-Space and Opportunity Mapping
15.3 Product Evolution and Market Life Cycle Analysis
15.4 Channel, Distributor, and Go-to-Market Assessment

16 Industry Developments and Strategic Initiatives

16.1 Mergers and Acquisitions
16.2 Partnerships, Alliances, and Joint Ventures
16.3 New Product Launches and Certifications
16.4 Capacity Expansion and Investments
16.5 Other Strategic Initiatives

17 Company Profiles

17.1 Catalent Inc.
17.2 Lonza Group AG
17.3 Recipharm AB
17.4 Aenova Group
17.5 Thermo Fisher Scientific Inc.
17.6 Pfizer Inc.
17.7 Novartis AG
17.8 Roche Holding AG
17.9 Sun Pharmaceutical Industries Limited
17.10 Teva Pharmaceutical Industries Ltd.
17.11 Dr. Reddy's Laboratories Limited
17.12 Viatris Inc.
17.13 Sanofi S.A.
17.14 Abbott Laboratories
17.15 Bayer AG
17.16 GlaxoSmithKline plc

簡介目錄圖表

List of Tables

Table 1 Global Solid Dosage Form Market Outlook, By Region (2023-2034) ($MN)
Table 2 Global Solid Dosage Form Market Outlook, By Dosage Form (2023-2034) ($MN)
Table 3 Global Solid Dosage Form Market Outlook, By Tablets (2023-2034) ($MN)
Table 4 Global Solid Dosage Form Market Outlook, By Immediate Release Tablets (2023-2034) ($MN)
Table 5 Global Solid Dosage Form Market Outlook, By Chewable Tablets (2023-2034) ($MN)
Table 6 Global Solid Dosage Form Market Outlook, By Effervescent Tablets (2023-2034) ($MN)
Table 7 Global Solid Dosage Form Market Outlook, By Enteric-Coated Tablets (2023-2034) ($MN)
Table 8 Global Solid Dosage Form Market Outlook, By Film-Coated Tablets (2023-2034) ($MN)
Table 9 Global Solid Dosage Form Market Outlook, By Orally Disintegrating Tablets (2023-2034) ($MN)
Table 10 Global Solid Dosage Form Market Outlook, By Capsules (2023-2034) ($MN)
Table 11 Global Solid Dosage Form Market Outlook, By Hard Gelatin Capsules (2023-2034) ($MN)
Table 12 Global Solid Dosage Form Market Outlook, By Soft Gelatin Capsules (2023-2034) ($MN)
Table 13 Global Solid Dosage Form Market Outlook, By Powders & Granules (2023-2034) ($MN)
Table 14 Global Solid Dosage Form Market Outlook, By Lozenges & Pastilles (2023-2034) ($MN)
Table 15 Global Solid Dosage Form Market Outlook, By Pellets & Mini-Tablets (2023-2034) ($MN)
Table 16 Global Solid Dosage Form Market Outlook, By Orally Disintegrating Films (2023-2034) ($MN)
Table 17 Global Solid Dosage Form Market Outlook, By Other Dosage Forms (2023-2034) ($MN)
Table 18 Global Solid Dosage Form Market Outlook, By Drug Release (2023-2034) ($MN)
Table 19 Global Solid Dosage Form Market Outlook, By Immediate Release (2023-2034) ($MN)
Table 20 Global Solid Dosage Form Market Outlook, By Modified Release (2023-2034) ($MN)
Table 21 Global Solid Dosage Form Market Outlook, By Sustained Release (2023-2034) ($MN)
Table 22 Global Solid Dosage Form Market Outlook, By Extended Release (2023-2034) ($MN)
Table 23 Global Solid Dosage Form Market Outlook, By Controlled Release (2023-2034) ($MN)
Table 24 Global Solid Dosage Form Market Outlook, By Delayed Release (Enteric-Coated) (2023-2034) ($MN)
Table 25 Global Solid Dosage Form Market Outlook, By Targeted Drug Delivery Systems (2023-2034) ($MN)
Table 26 Global Solid Dosage Form Market Outlook, By Route of Administration (2023-2034) ($MN)
Table 27 Global Solid Dosage Form Market Outlook, By Oral (2023-2034) ($MN)
Table 28 Global Solid Dosage Form Market Outlook, By Buccal (2023-2034) ($MN)
Table 29 Global Solid Dosage Form Market Outlook, By Sublingual (2023-2034) ($MN)
Table 30 Global Solid Dosage Form Market Outlook, By Therapeutic Area (2023-2034) ($MN)
Table 31 Global Solid Dosage Form Market Outlook, By Cardiovascular Diseases (2023-2034) ($MN)
Table 32 Global Solid Dosage Form Market Outlook, By Oncology (2023-2034) ($MN)
Table 33 Global Solid Dosage Form Market Outlook, By Central Nervous System (CNS) Disorders (2023-2034) ($MN)
Table 34 Global Solid Dosage Form Market Outlook, By Anti-Infectives (2023-2034) ($MN)
Table 35 Global Solid Dosage Form Market Outlook, By Gastrointestinal Disorders (2023-2034) ($MN)
Table 36 Global Solid Dosage Form Market Outlook, By Respiratory Diseases (2023-2034) ($MN)
Table 37 Global Solid Dosage Form Market Outlook, By Metabolic Disorders (2023-2034) ($MN)
Table 38 Global Solid Dosage Form Market Outlook, By Pain Management (2023-2034) ($MN)
Table 39 Global Solid Dosage Form Market Outlook, By Other Therapeutic Areas (2023-2034) ($MN)
Table 40 Global Solid Dosage Form Market Outlook, By Manufacturing Process (2023-2034) ($MN)
Table 41 Global Solid Dosage Form Market Outlook, By Direct Compression (2023-2034) ($MN)
Table 42 Global Solid Dosage Form Market Outlook, By Wet Granulation (2023-2034) ($MN)
Table 43 Global Solid Dosage Form Market Outlook, By Dry Granulation (2023-2034) ($MN)
Table 44 Global Solid Dosage Form Market Outlook, By Extrusion-Spheronization (2023-2034) ($MN)
Table 45 Global Solid Dosage Form Market Outlook, By Coating Technologies (2023-2034) ($MN)
Table 46 Global Solid Dosage Form Market Outlook, By Film Coating (2023-2034) ($MN)
Table 47 Global Solid Dosage Form Market Outlook, By Sugar Coating (2023-2034) ($MN)
Table 48 Global Solid Dosage Form Market Outlook, By Enteric Coating (2023-2034) ($MN)
Table 49 Global Solid Dosage Form Market Outlook, By Drug Type (2023-2034) ($MN)
Table 50 Global Solid Dosage Form Market Outlook, By Branded Drugs (2023-2034) ($MN)
Table 51 Global Solid Dosage Form Market Outlook, By Generic Drugs (2023-2034) ($MN)
Table 52 Global Solid Dosage Form Market Outlook, By Over-the-Counter (OTC) Drugs (2023-2034) ($MN)
Table 53 Global Solid Dosage Form Market Outlook, By Patient Demographics (2023-2034) ($MN)
Table 54 Global Solid Dosage Form Market Outlook, By Adult Population (2023-2034) ($MN)
Table 55 Global Solid Dosage Form Market Outlook, By Pediatric Population (2023-2034) ($MN)
Table 56 Global Solid Dosage Form Market Outlook, By Geriatric Population (2023-2034) ($MN)
Table 57 Global Solid Dosage Form Market Outlook, By End User (2023-2034) ($MN)
Table 58 Global Solid Dosage Form Market Outlook, By Pharmaceutical Companies (2023-2034) ($MN)
Table 59 Global Solid Dosage Form Market Outlook, By Contract Development & Manufacturing Organizations (CDMOs) (2023-2034) ($MN)
Table 60 Global Solid Dosage Form Market Outlook, By Research Institutes (2023-2034) ($MN)
Table 61 Global Solid Dosage Form Market Outlook, By Distribution Channel (2023-2034) ($MN)
Table 62 Global Solid Dosage Form Market Outlook, By Hospital Pharmacies (2023-2034) ($MN)
Table 63 Global Solid Dosage Form Market Outlook, By Retail Pharmacies (2023-2034) ($MN)
Table 64 Global Solid Dosage Form Market Outlook, By Drug Stores (2023-2034) ($MN)
Table 65 Global Solid Dosage Form Market Outlook, By Online Pharmacies (2023-2034) ($MN)